Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015
<p><strong>Background:</strong><br /> The diagnosis of neuroendocrine neoplasms (NENs) is often delayed. This first UK population-based epidemiological study of NENs compares outcomes with non-NENs to identify any inequalities.</p><br /> <p><strong>Me...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Nature
2019
|
| _version_ | 1826310031051587584 |
|---|---|
| author | Genus, TSE Bouvier, C Wong, KF Srirajaskanthan, R Rous, BA Talbot, DC Valle, JW Khan, M Pearce, N Elshafie, M Reed, NS Morgan, E Deas, A White, C Huws, D Ramage, J |
| author_facet | Genus, TSE Bouvier, C Wong, KF Srirajaskanthan, R Rous, BA Talbot, DC Valle, JW Khan, M Pearce, N Elshafie, M Reed, NS Morgan, E Deas, A White, C Huws, D Ramage, J |
| author_sort | Genus, TSE |
| collection | OXFORD |
| description | <p><strong>Background:</strong><br />
The diagnosis of neuroendocrine neoplasms (NENs) is often delayed. This first UK population-based epidemiological study of NENs compares outcomes with non-NENs to identify any inequalities.</p><br />
<p><strong>Methods:</strong><br />
Age-standardised incidence rate (ASR), 1-year overall survival, hazard ratios and standardised mortality rates (SMRs) were calculated for all malignant NENs diagnosed 2013–2015 from UK national Public Health records. Comparison with non-NENs assessed 1-year overall survival (1YS) and association between diagnosis at stage IV and morphology.</p><br />
<p><strong>Results:</strong><br />
A total of 15,222 NENs were identified, with an ASR (2013–2015 combined) of 8.6 per 100,000 (95% CI 8.5–8.7); 4.6 per 100 000 (95% CI, 4.5–4.7) for gastro-entero-pancreatic (GEP) NENs. The 1YS was 75% (95% CI, 73.9–75.4) varying significantly by sex. Site and morphology were prognostic. NENs (predominantly small cell carcinomas) in the oesophagus, bladder, prostate, and female reproductive organs had a poorer outcome and were three times more likely to be diagnosed at stage IV than non-NENs.</p><br />
<p><strong>Conclusion:</strong><br />
Advanced stage at diagnosis with significantly poorer outcomes of some NENs compared with non-NENs at the same anatomical site, highlight the need for improved access to specialist services and targeted service improvement.</p><br /> |
| first_indexed | 2024-03-07T07:44:29Z |
| format | Journal article |
| id | oxford-uuid:cab302ed-d410-4b14-99ed-663ec3fbccf6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:44:29Z |
| publishDate | 2019 |
| publisher | Springer Nature |
| record_format | dspace |
| spelling | oxford-uuid:cab302ed-d410-4b14-99ed-663ec3fbccf62023-05-23T07:53:40ZImpact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cab302ed-d410-4b14-99ed-663ec3fbccf6EnglishSymplectic ElementsSpringer Nature2019Genus, TSEBouvier, CWong, KFSrirajaskanthan, RRous, BATalbot, DCValle, JWKhan, MPearce, NElshafie, MReed, NSMorgan, EDeas, AWhite, CHuws, DRamage, J<p><strong>Background:</strong><br /> The diagnosis of neuroendocrine neoplasms (NENs) is often delayed. This first UK population-based epidemiological study of NENs compares outcomes with non-NENs to identify any inequalities.</p><br /> <p><strong>Methods:</strong><br /> Age-standardised incidence rate (ASR), 1-year overall survival, hazard ratios and standardised mortality rates (SMRs) were calculated for all malignant NENs diagnosed 2013–2015 from UK national Public Health records. Comparison with non-NENs assessed 1-year overall survival (1YS) and association between diagnosis at stage IV and morphology.</p><br /> <p><strong>Results:</strong><br /> A total of 15,222 NENs were identified, with an ASR (2013–2015 combined) of 8.6 per 100,000 (95% CI 8.5–8.7); 4.6 per 100 000 (95% CI, 4.5–4.7) for gastro-entero-pancreatic (GEP) NENs. The 1YS was 75% (95% CI, 73.9–75.4) varying significantly by sex. Site and morphology were prognostic. NENs (predominantly small cell carcinomas) in the oesophagus, bladder, prostate, and female reproductive organs had a poorer outcome and were three times more likely to be diagnosed at stage IV than non-NENs.</p><br /> <p><strong>Conclusion:</strong><br /> Advanced stage at diagnosis with significantly poorer outcomes of some NENs compared with non-NENs at the same anatomical site, highlight the need for improved access to specialist services and targeted service improvement.</p><br /> |
| spellingShingle | Genus, TSE Bouvier, C Wong, KF Srirajaskanthan, R Rous, BA Talbot, DC Valle, JW Khan, M Pearce, N Elshafie, M Reed, NS Morgan, E Deas, A White, C Huws, D Ramage, J Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015 |
| title | Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015 |
| title_full | Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015 |
| title_fullStr | Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015 |
| title_full_unstemmed | Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015 |
| title_short | Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: A UK nationwide cohort study 2013–2015 |
| title_sort | impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis a uk nationwide cohort study 2013 2015 |
| work_keys_str_mv | AT genustse impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT bouvierc impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT wongkf impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT srirajaskanthanr impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT rousba impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT talbotdc impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT vallejw impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT khanm impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT pearcen impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT elshafiem impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT reedns impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT morgane impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT deasa impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT whitec impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT huwsd impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 AT ramagej impactofneuroendocrinemorphologyoncanceroutcomesandstageatdiagnosisauknationwidecohortstudy20132015 |